KM-233

KM-233 is a synthetic compound that exhibits psychoactive properties. It is a derivative of cannabinoid, a class of chemicals that interact with the endocannabinoid system in the human body. KM-233 was developed in the early 21st century and has been the subject of ongoing research due to its potential therapeutic applications.

History[edit | edit source]

KM-233 was first synthesized in the early 2000s by a team of researchers led by Dr. Alexandros Makriyannis at the Northeastern University. The compound was developed as part of a broader effort to create synthetic cannabinoids that could be used in medical treatments.

Chemistry[edit | edit source]

KM-233 is a derivative of the cannabinoid class of chemicals. It is a complex molecule that is synthesized through a multi-step process. The compound is characterized by its unique structure, which includes a phenyl group and a naphthoyl group. These structural elements are believed to contribute to the compound's psychoactive properties.

Pharmacology[edit | edit source]

KM-233 interacts with the endocannabinoid system in the human body. This system is composed of cannabinoid receptors, which are found in various tissues throughout the body. KM-233 is believed to bind to these receptors, triggering a range of physiological responses.

The exact mechanism of action of KM-233 is not fully understood. However, it is known that the compound has a high affinity for the CB1 receptor, one of the two main types of cannabinoid receptors. This suggests that KM-233 may exert its effects primarily through interactions with this receptor.

Potential Therapeutic Applications[edit | edit source]

Research into the potential therapeutic applications of KM-233 is ongoing. The compound's ability to interact with the endocannabinoid system suggests that it may have potential uses in the treatment of a range of conditions, including chronic pain, inflammation, and certain neurological disorders.

However, much more research is needed to fully understand the potential benefits and risks of KM-233. As of now, the compound is not approved for use in any medical treatments.

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Translate this page: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.